Skip to main content
. 2017 Aug 24;8(46):80841–80852. doi: 10.18632/oncotarget.20591

Figure 5.

Figure 5

(A) Volume change of MCF-7 spheroids treated with blank particle, free (DOX + PTX), DOX/MCD + free PTX, F3 or F6 (at 100 ng/mL DOX and 20 ng/mL PTX) up to 21 days. (B) A close-up of growth curve of spheroids treated with free (DOX + PTX), DOX/MCD + free PTX, F3 or F6. (C) Viability of spheroids assessed by the acid phosphatase assay at the end of study (n=3, mean ±SD).